A Phase 2 interventional study of MK-3655 and Placebo in Nonalcoholic Steatohepatitis, sponsored by Merck Sharp & Dohme LLC. Terminated at 180 sites in 24 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Merck & Co., Inc.
Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2020, is one of 7 in phase 2, and was the 4th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 183 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 113 across the 10 interventional studies, 10 across the 1 observational. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,169 studies on the registry; 134 are open to participants now.
Of its 505 completed or terminated interventional studies of FDA-regulated products, 372 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks. The primary hypothesis of the study is that at least 1 dose of MK-3655 is superior to placebo with respect to the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following a 2-week placebo run-in, participants will receive MK-3655 50 mg by subcutaneous (SC) injection once every 4 weeks (Q4W) for 52 weeks.
Drug: MK-3655
Following a 2-week placebo run-in, participants will receive MK-3655 100 mg by SC injection Q4W for 52 weeks.
Drug: MK-3655
Following a 2-week placebo run-in, participants will receive MK-3655 300 mg by SC injection Q4W for 52 weeks.
Drug: MK-3655
Following a 2-week placebo run-in, participants will receive Placebo by SC injection Q4W for 52 weeks.
Drug: Placebo
MK-3655 50, 100 or 300 dose for injection
Also known as: NGM313
Matching placebo to MK-3655
Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 52 Weeks
The NASH Clinical Research Network (CRN) scoring system evaluated by Blinded Independent Central Review (BICR) was used to assess treatment response. The NASH CRN scoring scales were: lobular inflammation score (0-3); hepatocyte ballooning score (0-2); steatosis score (0-3); and fibrosis score (0-4). NASH resolution was defined as a score of 0-1 for inflammation, 0 for ballooning, and any grade of steatosis.
Time frame: Week 52
Percentage of Participants Who Experienced an Adverse Event (AE)
An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.
Time frame: Up to 64 weeks
Percentage of Participants Discontinuing Study Medication Due to an AE
An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.
Time frame: Up to 52 weeks
Mean Percent Relative Reduction From Baseline in Liver Fat Content (LFC) After 24 Weeks
LFC % was measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF) and evaluated by BICR. MRI-PDFF is a highly accurate noninvasive measure of the proportion of fat content of a tissue.
Time frame: Baseline and Week 24
Percentage of Participants With ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis Assessed With the NASH CRN Scoring System After 52 Weeks
Participants were evaluated with the NASH CRN scoring system with BICR with ≥1 stage improvement in fibrosis without worsening of steatohepatitis defined as no increase in the ballooning, inflammation, or steatosis scores.
Time frame: Week 52
Percentage of Participants With ≥2 Point Improvement in NAS With ≥1 Point Improvement in Inflammation or Ballooning Without Worsening of Fbrosis by Histology (Evaluated by BICR) After 52 Weeks
Participants with ≥2 point improvement in the NAS with ≥1 point improvement in inflammation or ballooning without worsening of fibrosis were assessed with the NASH CRN scoring system (evaluated by BICR). The NAS was calculated as the unweighted sum of the scores and ranges from 0-8 (highest activity).
Time frame: Week 52
Males and females with pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) aged 18 to 80 years (in Japan and Taiwan, aged 20 to 80 years were randomized in this study
| Milestone | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo |
|---|---|---|---|---|
| Started | 45 | 48 | 46 | 44 |
| Received 1st dose | 45 | 47 | 46 | 44 |
| Completed | 10 | 11 | 8 | 8 |
| Not completed | 35 | 37 | 38 | 36 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 2 |
| Withdrew: Study terminated by sponsor | 32 | 35 | 36 | 33 |
| Withdrew: Withdrawal by subject | 3 | 1 | 2 | 1 |
The NASH Clinical Research Network (CRN) scoring system evaluated by Blinded Independent Central Review (BICR) was used to assess treatment response. The NASH CRN scoring scales were: lobular inflammation score (0-3); hepatocyte ballooning score (0-2); steatosis score (0-3); and fibrosis score (0-4). NASH resolution was defined as a score of 0-1 for inflammation, 0 for ballooning, and any grade of steatosis.
| Percentage of Participants | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 52 Weeks | 16.7 | 14.3 | 17.6 | 5.9 |
An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.
| Percentage of Participants | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Experienced an Adverse Event (AE) | 73.3 | 70.2 | 76.1 | 77.3 |
An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.
| Percentage of Participants | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants Discontinuing Study Medication Due to an AE | 2.2 | 0 | 0 | 0 |
LFC % was measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF) and evaluated by BICR. MRI-PDFF is a highly accurate noninvasive measure of the proportion of fat content of a tissue.
| Percent Change | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo |
|---|---|---|---|---|
| Mean Percent Relative Reduction From Baseline in Liver Fat Content (LFC) After 24 Weeks | 30.1 (17.5 to 42.7) | 30.0 (18.2 to 41.8) | 37.2 (25.5 to 48.8) | 11.0 (-0.9 to 23.0) |
Participants were evaluated with the NASH CRN scoring system with BICR with ≥1 stage improvement in fibrosis without worsening of steatohepatitis defined as no increase in the ballooning, inflammation, or steatosis scores.
| Percentage of Participants | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis Assessed With the NASH CRN Scoring System After 52 Weeks | 22.2 | 38.1 | 29.4 | 17.6 |
Participants with ≥2 point improvement in the NAS with ≥1 point improvement in inflammation or ballooning without worsening of fibrosis were assessed with the NASH CRN scoring system (evaluated by BICR). The NAS was calculated as the unweighted sum of the scores and ranges from 0-8 (highest activity).
| Percentage of Participants | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With ≥2 Point Improvement in NAS With ≥1 Point Improvement in Inflammation or Ballooning Without Worsening of Fbrosis by Histology (Evaluated by BICR) After 52 Weeks | 33.3 | 47.6 | 35.3 | 29.4 |
Collected over Up to 64 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-3655 50 mg | 0/45 (0%) | 1/45 (2.2%) | 19/45 (42.2%) |
| MK-3655 100 mg | 0/48 (0%) | 1/47 (2.1%) | 26/47 (55.3%) |
| MK-3655 300 mg | 0/46 (0%) | 1/46 (2.2%) | 27/46 (58.7%) |
| Placebo | 0/44 (0%) | 8/44 (18.2%) | 21/44 (47.7%) |
| Event | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo |
|---|---|---|---|---|
| Sinoatrial blockCardiac disorders | 0/45 | 0/47 | 0/46 | 1/44 |
| CataractEye disorders | 0/45 | 0/47 | 0/46 | 1/44 |
| Abdominal painGastrointestinal disorders | 0/45 | 0/47 | 0/46 | 1/44 |
| Large intestine polypGastrointestinal disorders | 0/45 | 0/47 | 0/46 | 1/44 |
| Rectal haemorrhageGastrointestinal disorders | 0/45 | 0/47 | 0/46 | 1/44 |
| Non-cardiac chest painGeneral disorders | 0/45 | 0/47 | 0/46 | 1/44 |
| Pyelonephritis acuteInfections and infestations | 0/45 | 0/47 | 0/46 | 1/44 |
| Forearm fractureInjury, poisoning and procedural complications | 0/45 | 0/47 | 0/46 | 1/44 |
| Acute kidney injuryRenal and urinary disorders | 0/45 | 0/47 | 0/46 | 1/44 |
| NephrolithiasisRenal and urinary disorders | 0/45 | 0/47 | 0/46 | 1/44 |
| Event | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo |
|---|---|---|---|---|
| COVID-19Infections and infestations | 4/45 | 9/47 | 5/46 | 5/44 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/45 | 1/47 | 7/46 | 1/44 |
| DiarrhoeaGastrointestinal disorders | 4/45 | 7/47 | 5/46 | 3/44 |
| HypertensionVascular disorders | 2/45 | 6/47 | 6/46 | 1/44 |
| HeadacheNervous system disorders | 2/45 | 1/47 | 5/46 | 3/44 |
| Increased appetiteMetabolism and nutrition disorders | 2/45 | 5/47 | 4/46 | 0/44 |
| NauseaGastrointestinal disorders | 2/45 | 3/47 | 1/46 | 4/44 |
| PyrexiaGeneral disorders | 2/45 | 2/47 | 2/46 | 4/44 |
| Back painMusculoskeletal and connective tissue disorders | 1/45 | 3/47 | 4/46 | 3/44 |
| NasopharyngitisInfections and infestations | 2/45 | 4/47 | 2/46 | 0/44 |
| Age, Continuous(Years) | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 59.6 ± 8.9 | 54.3 ± 12.3 | 56.6 ± 11.3 | 55.8 ± 10.1 | 56.5 ± 10.8 |
| Sex: Female, Male(Participants) | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 25 | 20 | 23 | 19 | 87 |
| Male | 20 | 28 | 23 | 25 | 96 |
| Ethnicity (NIH/OMB)(Participants) | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 12 | 13 | 17 | 18 | 60 |
| Not Hispanic or Latino | 33 | 34 | 28 | 25 | 120 |
| Unknown or Not Reported | 0 | 1 | 1 | 1 | 3 |
| Race (NIH/OMB)(Participants) | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 15 | 18 | 16 | 16 | 65 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 0 | 2 |
| Black or African American | 3 | 2 | 1 | 1 | 7 |
| White | 26 | 28 | 27 | 26 | 107 |
| More than one race | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Baseline Fibrosis Stage(Participants) | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo | Total |
|---|---|---|---|---|---|
| Stage 2 | 21 | 22 | 21 | 21 | 85 |
| Stage 3 | 24 | 26 | 25 | 23 | 98 |
| Percent Liver Fat Content(Participants) | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo | Total |
|---|---|---|---|---|---|
| <20% | 30 | 23 | 30 | 31 | 114 |
| ≥ 20% | 15 | 25 | 16 | 13 | 69 |
| Type 2 Diabetes Mellitus (T2DM)(Participants) | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo | Total |
|---|---|---|---|---|---|
| Yes | 22 | 25 | 25 | 24 | 96 |
| No | 23 | 23 | 21 | 20 | 87 |
| Region(Participants) | MK-3655 50 mg | MK-3655 100 mg | MK-3655 300 mg | Placebo | Total |
|---|---|---|---|---|---|
| Japan | 11 | 12 | 11 | 11 | 45 |
| East Asia excluding Japan | 6 | 5 | 5 | 5 | 21 |
| Other | 28 | 31 | 30 | 28 | 117 |
Showing the first 100 of 180 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Nov 2020 to primary completion in Apr 2023, 29 months.
Results were first posted in Apr 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →